Establishment and evaluation of prediction model for multiple disease classification based on gut microbial data

Sohyun Bang¹,², DongAhn Yoo³, Soo-Jin Kim³, Soyun Jhang¹,², Seoae Cho² & Heebal Kim¹,²,³

Diseases prediction has been performed by machine learning approaches with various biological data. One of the representative data is the gut microbial community, which interacts with the host’s immune system. The abundance of a few microorganisms has been used as markers to predict diverse diseases. In this study, we hypothesized that multi-classification using machine learning approach could distinguish the gut microbiome from following six diseases: multiple sclerosis, juvenile idiopathic arthritis, myalgic encephalomyelitis/chronic fatigue syndrome, acquired immune deficiency syndrome, stroke and colorectal cancer. We used the abundance of microorganisms at five taxonomy levels as features in 696 samples collected from different studies to establish the best prediction model. We built classification models based on four multi-class classifiers and two feature selection methods including a forward selection and a backward elimination. As a result, we found that the performance of classification is improved as we use the lower taxonomy levels of features; the highest performance was observed at the genus level. Among four classifiers, LogitBoost–based prediction model outperformed other classifiers. Also, we suggested the optimal feature subsets at the genus-level obtained by backward elimination. We believe the selected feature subsets could be used as markers to distinguish various diseases simultaneously. The finding in this study suggests the potential use of selected features for the diagnosis of several diseases.

Machine learning technology has been applied in various fields and has become a useful strategy in the field of biotechnology, especially for predicting diseases and supporting medical diagnosis¹–³. In order to predict diseases, biological data including gene expression, genotype, and methylation level can be employed⁴,⁵. Moreover, the realms of biological data have been extended to include the microbial communities due to their association with the host’s immune system⁶. Microbial communities facilitate the development and function of the immune cells at both the mucosal and nonmucosal sites⁷. Their regulation of the immune system is involved in various diseases⁸. Such association has been identified in diseases like multiple sclerosis (MS), juvenile idiopathic arthritis (JIA), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), stroke, acquired immune deficiency syndrome (AIDS), and colorectal cancer (CRC)⁹–¹⁴.

Some of the well-known researches have attempted to establish a disease-prediction model based on the gut microbiome data from healthy individuals and patients, and have discovered that gut microbiome data can be applied to predict specific diseases¹². Patients with irritable bowel syndrome and healthy individuals were classified using Random forest algorithm¹⁵. Other diseases such as liver cirrhosis, colorectal cancer, inflammatory bowel diseases, obesity, and type 2 diabetes were distinguished with a healthy status using machine learning approaches¹⁶. Most of these studies have focused mainly on diagnosing only one disease, and so far, there have been few attempts to predict multiple diseases at once.

The potential of multi-classification using microbiome data is being shown in recent studies¹⁷,¹⁸. In the case of classifying various body parts, a previous study performed multi-classification based on KNN and probabilistic neural networks¹⁹. In another study, multi-classification of three different diseases was demonstrated using...
selected metagenomic biomarkers. Similarly, in our study, we hypothesized that various diseases could be classified using gut microbiome data from 16S rRNA sequencing. To investigate the possibility of classification on various diseases based on the microbial community, we collected a total of 1,079 metagenome data from healthy individuals and patients with following diseases in six studies: MS, JIA, ME/CFS, AIDS, CRC, and Stroke. To combine data, we preprocessed data using normalization and statistical method. We classified six diseases listed above using the abundance of microorganisms at the phylum, class, order, family, and genus levels as features. We built classification models based on the multi-class classifiers such as LogitBoost, support vector machine (SVM), K nearest neighbor (KNN) and logistic model tree (LMT). Moreover, we constructed a feature subset using two feature selection methods. We compared the performance of classification in three factors: 1) taxonomy levels of features, 2) four classifiers and 3) feature selection methods.

Results

Preprocessing of data to reduce biases from meta-analysis. Metagenome data from 1,079 individuals were collected for the healthy (control samples) and patients with one of six diseases including MS, JIA, ME/CFS, AIDS, CRC, and Stroke (Table 1). The study for HIV produced the highest number of average reads (89.9 M) while the study for Stroke had the lowest (4.9 M). Out of all individuals, six individuals with less than 7067.68 reads (<5% of the average) were removed. Thus, the total of 1,073 individuals-696 patients and 377 healthy samples-was used for further analysis. The abundance of microorganisms at the phylum, class, order, family, and genus levels for 1,073 samples were normalized to correct for variations arising from use of different studies (Fig. 1A). After Trimmed Mean of M values (TMM) normalization for the abundance of microorganisms, we compared the abundance of healthy samples from six studies. For the reason to minimize the study-dependent differences, we removed the microorganisms that are differentially abundant between studies (false discovery rate (FDR) < 0.05). Average of 16% of bacteria (5, 21, 42, 74 and 199 at the phylum, class, order, family, and genus levels, respectively) remained (Fig. 1). To further normalize the microbiome abundance of samples from different studies, quantile normalization was performed using the healthy samples as the baseline. The normalized

| SRA_study | Disease | Body site | # of case samples | # of control samples | Average reads per sample (std) |
|-----------|---------|-----------|-------------------|----------------------|------------------------------|
| ERP010468 | Stroke  | Gut       | 141               | 92                   | 4.9 M(0.4 M)                 |
| ERP013262 | JIA     | Gut       | 29                | 29                   | 9.2 M(2 M)                   |
| ERP014628 | ME/CFS  | Gut       | 49                | 39                   | 52.5 M(17.1 M)               |
| SRP068240 | HIV1    | Gut       | 191               | 33                   | 69.9 M(69.9 M)               |
| SRP073172 | CRC     | Gut       | 263               | 141                  | 14.2 M(10.3 M)               |
| SRP075039 | MS      | Gut       | 29                | 44                   | 31.2 M(5.5 M)                |

Table 1. Summary of collected metagenome studies.

Figure 1. Experimental design and data processing for meta-analysis. (A) A diagram representing a whole experimental design for this research. This research consists of two major steps for analysis: (1) The process of normalization and removing features for meta-analysis; (2) The step of classification analysis to predict six diseases in integrated metagenome data across the six diseases. (B) Number of features at five taxonomy levels. “Total” represents the total number of features before preprocessing of data. “Filtering” represents the number of features after steps for removing features in preprocessing of data.
abundance of microorganisms for 696 samples obtained in this preprocessing step was considered as features in the subsequent classification analysis.

**Classification performance at five taxonomy levels.** To elucidate the effect of different taxonomy levels on the classification, we assessed the performance of the classification using different sets of features such as the abundance of microorganisms at the phylum, class, order, family, and genus levels. The average of accuracies of four classifiers including KNN, LMT, LogitBoost and SVM was improved as we used the lower taxonomy levels as features (Fig. 2A). The average of accuracies at the phylum, class, order, family and genus levels were 55, 69.9, 76.5, 80.4 and 90.4% respectively. The accuracy at the genus level was 35.4% higher than that at the phylum level. On the other hand, the difference of accuracies between classifiers with highest accuracy (LogitBoost) and lowest accuracy (KNN) was 11.92%. Thus, we found that the effect of taxonomy levels on the classifier performance was greater than that of using different classifiers.

We assumed that some of the microorganisms used in the above classification might not be associated with the diseases because only a few microorganisms were found to be closely related to human health or disease\cite{20}. Hence, we performed feature selection to find features that can classify diseases more accurately. For feature selection, we used forward selection (FS) and backward elimination (BE) in four classifiers with microbial abundance at five taxonomy levels. Feature selection enhanced accuracies by 2.6%, 2.4% and 2.7% at the order, family and genus levels, respectively, while its effects were not as remarkable in phylum and class levels (0.6% and 0.4% enhanced) (Fig. 2B). The highest accuracy improvement of 2.7% due to feature selection was observed when using features of abundance at the genus level. By feature selection, 5, 21, 42, 74, and 199 number of features were reduced to 2.75, 16.5, 29.1, 45.3, and 139.5 on average in phylum, class, order, family and genus levels, respectively (Fig. 2C). The highest number of features was removed at the genus level. Considering the increase of accuracies and number of reduced features, feature selection was more effectively performed at the genus level.

---

**Figure 2.** Classification performance by taxonomy levels and feature selection methods. (A) Accuracies by taxonomy levels. Individual dots symbolize the accuracy of four classifiers. Blue dots with error bar represents the mean of the accuracies in each taxonomy. (B) Mean of Accuracies in four classifiers by taxonomy levels and feature selection method. The color of bars shows the feature selection method. “All” indicates that all features without feature selection are used for classifications. “FS” and “BE” indicates the features subset from FS and BE respectively. Error bar represents the standard error of accuracies at each taxonomy level and feature selection method. (C) Mean of number of features in four classifiers by taxonomy levels and feature selection method.
Comparison of classification performance at the genus level. We compared classifiers and feature selection methods based on the performance at the genus level which showed the highest performance among five taxonomy levels. The classification was conducted using 10-fold cross-validation (CV), and accuracies were averaged over three runs of 10-fold CV. Four classifiers affected the performance of classification (Fig. 3A). The average accuracy was the highest in LogitBoost (93.6%) followed by LMT (92.4%), SVM (91.6%), and KNN (81.5%). The difference of accuracies between classifiers with the highest accuracy (LogitBoost) and that with the lowest (KNN) was 12%. In Fig. 2A, the difference in performance between LogitBoost and KNN increases as the taxonomy level gets lower. Regarding this aspect, the large difference (12%) between LogitBoost and KNN might come from the highest feature number at the genus level.

When we use the optimal feature sets from FS and BE, the average accuracies of the four classifiers were increased from 90.4% to 92.9% and 93.3% (FS and BE). Especially, the accuracies from KNN algorithms showed a remarkable increase from 81.8% to 86.7% and 87.5% when FS and BE were used. In all four classifiers, BE enhanced higher accuracies than FS by 0.09%, 1.19%, 0.09% and 0.43% in LogitBoost, LMT, SVM, and KNN, respectively. In LMT classifier, BE achieved the most effectively enhanced accuracies. The average number of features was reduced from 199 to 143.5 and 135.5 (FS and BE, respectively) across four classifiers (Fig. 3B). Even though BE decreased the number of features much more compared to FS on average, the reduced number of features did not follow this trend in all classifiers. FS effectively reduced the number of features in LogitBoost algorithms, while BE did in LMT algorithm. In summary, performing feature selection enabled us to obtain the subset of features which enhanced the overall performance of the classification in all classifiers. More importantly, higher accuracy was achieved when a lower number of features were used.

Accuracy, false positive and false negative error rate per six diseases. We examined the classification performance by calculating the accuracy of false positive rate (FPR) and false negative rate (FNR), which is a calculation method used to classify into two classes\(^1\). Additionally, we investigated the performance of classification per diseases by obtaining feature set from BE with the highest performance. In LogitBoost algorithm, which had the highest performance among classifiers, average accuracy by disease was 98.1%, which is higher than overall accuracy of BE (93.6%) (Table 2). This increase of accuracy was caused by a higher number of true negatives because we applied calculation for evaluating a binomial classification for each disease. For the same reason, the mean of FPR (1.26%) was lower than that of FNR (13.86%). Since FPR divides true positive by sum of a true negative and true positive which makes it inversely proportional to true negative, in our case, as the number of true negative jumps to a greater number, a lower value of FPR was observed. Out of six diseases, CRC showed the highest FPR (3.7%) of all the diseases, which implies the classification of 3.7% of patients with non-CRC diseases as CRC. The lowest accuracy in CRC (96.84%) among six diseases was caused by a highest FPR. As FNR of the diseases showed high variance between diseases, CRC, HIV1, and Stroke (2.28, 0.36, 3.78%) were less than 5% of FNR, whereas JIA, ME/CFS, and MS (16.09, 28.47, 32.18%) were more than 10% of FNR. Diseases with high FNR including JIA, ME/CFS, and MS showed higher occurrences of misclassification into other diseases.
contingency tables, we observed that diseases with a high FNR are highly likely to be classified as CRC which had the highest FNR of all diseases.

The diseases with high FPR and FNR in other algorithms were the same as that in LogitBoost algorithm. CRC had the highest FPR and the lowest accuracy among diseases in other classifiers. JIA, ME/CFS, and MS had higher FNR compared to other diseases in other classifiers. In KNN algorithm, CRC showed the highest FPR of 12.93%, while other classes showed FPR lower than 3%. Also, FNR of JIA, ME/CFS and MS (34.48, 64.58 and 77.01%) were higher than that of other classes with FNR below 8%. However, classes with higher FPR (or FNR) in KNN showed higher FPR (or FNR) compared to that in LogitBoost. FPR of CRC in KNN (12.93%) was three times higher than that in LogitBoost (3.7%). FNR of JIA, ME/CFS and MS (58.69%; mean of three classes) in KNN was twice as much as that in LogitBoost (25.58%; mean of three classes).

Identification of the disease-related microbial features. Through feature selections, we detected feature subsets that distinguish six diseases with the highest performance per classifier. Selected features can be used for microbial marker as they may be a shred of evidence of a close relatedness with the six diseases. Thus, we used subsets that distinguish six diseases with the highest performance per classifier. Selected features can be used to elucidate further on the importance of these genera in classification, we looked closely into the rank of individual genus. The rank of the genus to be added or dropped during the feature selection procedure could be of interest as the features with greater performance tends to be added earlier or dropped later during feature selection. Therefore, we considered the rank of genus in the selection. Among 17 genera, only PSBM3 was selected in order of no more than five, which is less than 5% of 199 genera. PSBM3 belongs to a bacterial family called Erysipelotrichaceae, which is associated with immune system. Erysipelotrichaceae was coated by IgA and their abundance had a positive correlation with tumor necrosis factor alpha levels. Specifically, PSBM3 is associated with invariant natural killer T, which had a crucial role in pathogenesis of inflammatory diseases.

Discussion
We compared the performance of classification for six diseases in terms of three factors: 1) taxonomy level, 2) classifier and 3) feature selection method. Among the three factors, altering taxonomy levels influenced the classification performance the most. Moreover, we found that the performance improved as we used lower taxonomy level as features, which is consistent with a previous finding. Microorganisms at lower taxonomy levels have been used to investigate their impact on the host because they help to estimate the function more specifically. This suggests the necessity of using the technology of assigning microorganisms with high resolution in the classification of various diseases. In addition to the taxonomy level, we also evaluated the classification performance of four classifiers. Among the four classifiers, LogitBoost showed the highest performance. LogitBoost algorithm is a boosting model which process interactions effectively and robust to outliers, missing data, and many correlated as well as less important variables. This might have a positive influence on enhancing the performance of the classification of multiple diseases. On the other hand, KNN showed the lowest performance. KNN algorithm is reasonably well solved for a smaller number of features. The performance of KNN algorithm was especially lower at the genus level compared to the other classifiers.

| Classifications | Accuracy | HIV1 | JIA | ME/CFS | MS | Stroke | Average |
|-----------------|----------|------|-----|--------|----|--------|--------|
| LogitBoost      | 96.84 ± 0.43 | 99.71 ± 0.14 | 98.52 ± 0.22 | 96.93 ± 0.46 | 98.28 ± 0.29 | 98.32 ± 0.46 | 98.1 ± 0.33 |
| LMT             | 95.93 ± 0.3 | 98.66 ± 0.22 | 98.95 ± 0.22 | 96.26 ± 0.57 | 98.18 ± 0.44 | 98.8 ± 0.22 | 97.8 ± 0.33 |
| SVM             | 95.59 ± 0.5 | 98.85 ± 0.25 | 98.28 ± 0.38 | 96.46 ± 0.08 | 98.08 ± 0.22 | 98.75 ± 0.22 | 97.67 ± 0.28 |
| KNN             | 90.28 ± 0.3 | 97.27 ± 0.43 | 97.27 ± 0. | 94.73 ± 0.36 | 96.41 ± 0.14 | 96.55 ± 0.5 | 95.42 ± 0.29 |

Table 2. Evaluation of performance per class in feature subset of BE in four algorithms. The model was validated by 10-fold cross-validation and repeated three times. Values represent the mean of accuracy ± variance.
Table 3. Robust genera subset from two feature selection methods in four classifiers. We present 17 genera selected in combination of four classifiers and two feature selection method. Column represent “Classifier/feature selection method”. The figures in the table show the order of genera in selection steps. The lower number (figure) indicates the more importance for genera in terms of performance.

| Genera          | Logit Boost/FS | LogitBoost/BE | LMT/FS | LMT/BE | SVM/FS | SVM/BE | KNN/FS | KNN/BE | Mean of order |
|-----------------|----------------|---------------|--------|--------|--------|--------|--------|--------|--------------|
| PSBM3           | 3              | 2             | 5      | 3      | 3      | 2      | 3      | 3      | 3            |
| Candidatus Azobacteroides | 6               | 10            | 7      | 8      | 10     | 122    | 5      | 60     | 28.5         |
| Cetobacterium   | 10             | 19            | 6      | 25     | 19     | 31     | 17     | 154    | 35.125       |
| Ralstonia       | 46             | 17            | 93     | 14     | 27     | 16     | 45     | 24     | 35.25        |
| Proteus         | 32             | 3             | 126    | 15     | 6      | 27     | 9      | 78     | 37           |
| Flavobacterium  | 33             | 7             | 98     | 51     | 44     | 17     | 49     | 7      | 38.25        |
| Moryella        | 8              | 105           | 1      | 77     | 7      | 1      | 103    | 65     | 45.875       |
| Citrobacter     | 11             | 89            | 20     | 5      | 88     | 7      | 135    | 13     | 46           |
| Anaerofustis    | 23             | 6             | 35     | 73     | 66     | 26     | 129    | 36     | 49.25        |
| Dickeya         | 18             | 26            | 27     | 10     | 171    | 11     | 28     | 111    | 50.25        |
| Owenweeksia     | 52             | 16            | 95     | 6      | 8      | 131    | 68     | 58     | 54.25        |
| Salmonella      | 22             | 69            | 99     | 61     | 49     | 59     | 125    | 77     | 70.125       |
| Pedococcus      | 99             | 93            | 46     | 82     | 67     | 45     | 145    | 19     | 74.5         |
| Variovorax      | 80             | 127           | 54     | 79     | 133    | 79     | 58     | 57     | 83.375       |
| Leuconostoc     | 83             | 112           | 96     | 63     | 63     | 91     | 94     | 88     | 86.25        |
| Marvinbryantia  | 106            | 156           | 118    | 43     | 80     | 113    | 78     | 89     | 97.875       |
| Novosphingobium | 51             | 151           | 121    | 48     | 90     | 82     | 116    | 151    | 101.25       |

We constructed feature subsets using FS and BE. FS and BE achieve improved accuracy because they find the optimal feature sets by interacting with classifiers34. On the other hand, FS and BE require expensive computation times with a large number of features. This might rarely cause their application in the gut microbiome data. In this study, we showed that the selected microorganisms with FS and BE could boost the performance, especially, the feature subsets selected by BE had higher performance than that by FS. Since BE starts with the full set of features, it is easier to capture the interactive features, such that this advantage of BE can take into account the complex network of microbe-microbe interactions. Microbes interact with each other by forming microbial guilds where they provide the substrate to each other, and even some anaerobic bacteria in the gut were demonstrated to perform metabolic cross-feeding19. Therefore, a group of microorganisms is more related to human health than individual ones, which is why a higher performance of BE was observed.

While performing the feature selection, we proposed the feature subsets that are potentially related to six different diseases. However, the feature subsets selected in this study may not contain all the microorganisms associated with the six diseases due to the data preprocessing. We preprocessed the data with various measures such as employing strict criteria when collecting the data from various studies and performing TMM and quantile normalization to minimize the variations between the studies. In addition, the samples were composed of a variety of nationalities which influence dietary habits, thereby affecting the composition of the gut microbiome. Some features, which might be affected by variation among samples, were deleted to reduce heterogeneity across different studies, which might cause by the effect of nationality. Thus, a few features significantly related to the six diseases may have been removed from this process. Despite the limitation of data preprocessing from different studies, we detected microorganisms associated with the six diseases.

Association with gut microbiome and health suggested the potential roles of gut microorganisms in precision medicine approach34. Disease-related microorganisms can be used as microbial markers to detect diseases using well-known methods including metagenomics, phylogenetic microarrays, DNA fingerprinting techniques, and qPCR28. Most of the previous disease studies on metagenome data focused on identification of biomarkers by comparing two groups of samples (case-control study)35. However, focusing on one disease may not be able to detect biomarker bacteria that is specific to that disease. This is because the same microorganisms can be differentially abundant in several diseases since the immune system of the host is influenced by the certain gut microbiome community that can be vulnerable to various diseases8,36. On the other hand, the selected features in this study are expected to have disease specific profiling of microbial communities, which can be used for biomarkers to distinguish various diseases simultaneously. For example, PSBM3 (belongs to Family Erysipelotrichaceae) was an important feature in eight feature subsets. In the previous study, family Erysipelotrichaceae was studied to perform metabolic cross-feeding19. Therefore, a group of microorganisms is more related to human health than individual ones, which is why a higher performance of BE was observed.

As a result of the classification per diseases investigation, we found that JIA, ME/CFS and MS are classified into CRC. According to previous studies, CRC is related to fatigue symptom, which is a similar symptom with ME/CFS. The fatigue by CRC can be affected by sarcopenia, characterized by muscle loss, which demonstrates the relationship between ME/CFS and CRC25. Moreover, there is a possible relationship between cancer risk and MS, which can cause diagnostic neglect17. Though, the association between CRC and JIA has not been identified.
In summary, we presented the classification of six diseases using a machine learning algorithm and gut microbiome data. By evaluating performance in various perspectives, we showed the effect of bacterial abundance of different taxonomy levels and various classifier on performance of classification. Furthermore, we suggested the optimal genus subsets that can be potentially used as microbial markers to distinguish multiple diseases through feature selection, which confers the potential use for multi-diseases classification in the diagnosis of diseases.

Materials and Methods

Collection of the gut microbiome data related to six diseases. For disease prediction based on the metagenome data sets of gut microbial communities, large numbers of metagenome samples were collected from the European Bioinformatics Institute (EBI) database (https://www.ebi.ac.uk/metagenomics/). To minimize the biases caused by different experimental protocols, data were collected with several criteria: (1) 16S rRNA based metagenome data through the stool sampling, which is widely used approach at present, (2) sequencing platforms including 454 and Illumina's, (3) using first measurement in case of longitudinal data to ensure independence assumption and (4) EBI pipeline v2.0 or v3.0 (https://www.ebi.ac.uk/metagenomics/pipelines/3.0) for identifying and quantifying the OTUs. In EBI pipeline, several tools used are as following: (1) Trimmomatic (v0.32) for quality check and trimming of low quality reads; (2) SeqPrep (v1.1) to merge paired-end reads to generate overlapped read; (3) RNASelector (v1.0.1) to filter out of non-ribosomal RNA; (4) QIME (v1.9.0) for OTU identification and quantification. From this pipeline, gut microbial communities data was generated at various taxonomic levels such as phylum, class, order, family, and genus based on the Greengenes 16S rRNA database.

Preprocessing of the metagenomic data derived from different studies. Samples with less than 5% of the average number of reads were removed. The abundance of microorganisms at five taxonomy levels including phylum, class, order, family, and genus levels was used as features. We performed a TMM normalization for the abundance of features using edgeR45. To reduce heterogeneity across different studies, the studies showing differential abundance of healthy samples between six studies were removed. We performed a log-likelihood ratio test by considering the abundance of features as negative binomial distribution46. In the statistical test, FDR procedure was used to adjust multiple testing error47 and 5% significance level was used for a significant result.

We further normalized the abundance with quantile normalization to produce a similar distribution of samples48. For quantile normalization, two types of baselines can be considered to calculate normalized values: (1) global mean vector derived from each quantile of features and (2) specific baseline vector. As we assumed that distribution of all control samples are similar, the second approach was employed using only the healthy samples to create the baseline49.

Classifiers to distinguish various diseases using the gut microbial data. In this study, four classifiers which have previously shown high multi-group classification performance were employed including KNN, LogitBoost, LMT and SVMs with sequential minimal optimization (SMO)50,51. The KNN implies a classifier capable of multi-groups classification. The LogitBoost is a developed boosting algorithm that can handle multiclass problems by considering multiclass logistic loss52. The LogitBoost has been applied to predict protein structural classes53 and places of origin for pigs with high performance54. The LMT is based on a regression tree that has logistic models on the leaves55. In predictions related to medical application including prediction of response to antiretroviral combination therapy or autism spectrum disorder, LMT showed an advantage over the other methods56,57. The SMO has been shown to be an effective method for SVM on classification tasks without a quadratic programming solver. The KNN and SVM classifiers are the most widely used methods and they have been applied successfully in numerous studies58,59.

We performed classification analysis with the four classifiers, implemented in the RWeka package of the R software60 with the command line of "IBk(class~., data = InputData, control = Weka_control(K = Selected Parameter), na.action = NULL)", "LogitBoost(class~., data = InputData, control = Weka_control(I = Selected Parameter), na.action = NULL)", "LMT(class~., data = InputData, na.action = NULL)", and SMO(class~., data = InputData, control = Weka_control(K = list(kernel, G = Selected Parameter), C = Selected Parameter), na.action = NULL) for KNN, LogitBoost, LMT, and SVM. To assess the performance of classification, 10-fold cross-validation was used.

To select a parameter for the classifier, we used a greedy method that explores all parameter and used the parameter with the best performance. In KNN, parameter K was chosen in 3, 5, 7, 9, 11, 13, 15 (Table S1). In LogitBoost, the parameter I was selected in the range from 1 to 40 (Table S2). In SVM (for RBF kernel), the parameter G and parameter C were regulated in [1e-4, 1e-3, 1e-2, ..., 10, 0.1, ..., 1000] respectively (Table S3). The parameters with the highest accuracy were chosen for each taxonomy level (Table S4). For the parameters with same accuracy, the one with lower value was selected.

Feature selection using wrapper method. We searched for a feature subset that enhances performance of classification through a wrapper feature-selection approach61 including FS and BE54. In FS, starting from the single feature with the highest accuracy, we added the feature that improves the performance the most. We continued to add features one-by-one until no more feature is left to be added. In BE, starting with all features we subtracted features one-by-one to give the highest accuracy. With the feature selection process, we obtained the feature subset showing the highest accuracy.

Data Availability

Raw sequencing data and patient metadata are available at the NCBI Sequence Read Archive (SRP073172, SRP068240, ERP013262, ERP014628, SRP075039 and ERP10458).
References

1. Cruz, J. A. & Wishart, D. S. Applications of machine learning in cancer prediction and prognosis. Cancer Informatics 2 (2006).
2. Saadat, P. Machine learning for detection and diagnosis of disease. Annu. Rev. Biomed. Eng. 8, 537–565 (2006).
3. Kukur, M., Kononenko, I., Grobel, C., Kraji, K. & Fetichi, J. Analysing and improving the diagnosis of ischaemic heart disease with machine learning. Artificial intelligence in medicine 16, 25–50 (1999).
4. Cho, S. & Won, H.-H. In Proceedings of the First Asia-Pacific bioinformatics conference on Bioinformatics 2003—Volume 19. 189–198 (Australian Computer Society, Inc.).
5. Knights, D., Costello, E. K. & Knight, R. Supervised classification of human microbiota. FEMS Microbiol Rev 35, 343–359, https://doi.org/10.1111/j.1574-6976.2010.00251.x (2011).
6. Rooks, M. G. & Garrett, W. S. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16, 341–352, https://doi.org/10.1038/nr16-42 (2016).
7. Maranduba, C. M. D. C. et al. Intestinal microbiota as modulators of the immune system and neuroimmune system: impact on the host health and homeostasis. Journal of immunology research 2015 (2015).
8. Kinross, J. M., Darzi, A. W. & Nicholson, J. K. Gut microbiome–host interactions in health and disease. Genome medicine 3, 1 (2011).
9. Jangi, S. et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 7, 12015, https://doi.org/10.1038/ncomms12015 (2016).
10. Baxter, N. T., Kounoupsara, C. C., Rogers, M. A., Ruffin, M. T. & Schloss, P. D. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Microbiome 4, 59, https://doi.org/10.1186/s40661-016-0205-y (2016).
11. Noguera-Julian, M. et al. Gut Microbiota Linked to Sexual Preference and HIV Infection. ElBioMedicine 5, 135–146, https://doi.org/10.1016/j.embio.2016.01.032 (2016).
12. Giletteau, J. et al. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 4, 30, https://doi.org/10.1186/s40661-016-0171-4 (2016).
13. Di Paola, M. et al. Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status. Front Microbiol 7, 1703, https://doi.org/10.3389/fmicb.2016.01703 (2016).
14. Baxter, N. T., Ruffin, M. T., Rogers, M. A. & Schloss, P. D. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med 8, 37, https://doi.org/10.1186/s13073-016-0290-3 (2016).
15. Saulnier, D. M. et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 141, 1782–1791 (2011).
16. Pasolli, E., Truong, D. T., Malik, F., Waldron, L. & Segata, N. Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights. PLoS Comput Biol 12, e1004977, https://doi.org/10.1371/journal.pcbi.1004977 (2016).
17. Liu, Z., Hsiao, W., Cantarel, B. L., Dribe, E. F. & Fraser-Liggett, C. Sparse distance-based learning for simultaneous multiclass classification and feature selection of metagenomic data. Bioinformatics 27, 3247–3249 (2011).
18. Statnikov, A., Aliferis, C. F., Tsamardinos, I., Hardin, D. & Levy, S. A comprehensive evaluation of multiclassification methods for microarray gene expression cancer diagnosis. Bioinformatics 21, 631–643 (2005).
19. Wu, H. et al. Metagenomics Biomarkers Selected for Prediction of Three Different Diseases in Chinese Population. BioMed research international 2018 (2018).
20. Norman, J. M. et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160, 447–460 (2015).
21. Sokolova, M. & Lapalme, G. A systematic analysis of performance measures for classification tasks. Information Processing & Management 45, 427–437 (2009).
22. Segata, N. et al. Metagenomic biomarker discovery and exploration. Genome biology 12, R60 (2011).
23. Kaakoush, N. O. Insights into the role of Erysipelotrichaceae in the human host. Frontiers in cellular and infection microbiology 5, 84 (2015).
24. Dinh, D. M. et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. The Journal of infectious diseases 211, 19–27 (2014).
25. Palm, N. W. et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 158, 1000–1010 (2014).
26. H. Hermann-Bank, M. L., Skovgaard, K., Stockmarr, A., Larsen, N. & Mølbak, L. The Gut Microbiota assay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity. BMC genomics 14, 788 (2013).
27. Manor, O., Levy, R. & Borenstein, E. Mapping the inner workings of the microbiome: genomic-and metagenomic-based study of metabolic and metabolic interactions in the human microbiome. Cell metabolism 20, 742–752 (2014).
28. Neecker, C., McNally, C. P., Eng, A. & Borenstein, E. High-resolution characterization of the human microbiome. Translational Research 179, 7–23 (2017).
29. Hastie, T., Rosset, S., Zhu, J. & Zou, H. Multi-class adaBoost. Statistics and its Interface 2, 349–360 (2009).
30. Zhang, G. & Fang, B. LogitBoost classifier for discriminating thromophilic and mesophilic proteins. Journal of biotechnology 127, 417–424 (2007).
31. Spratt, H., Ju, H. & Brasier, A. R. A structured approach to predictive modeling of a two-class problem using multidimensional data sets. Methods 61, 73–85 (2013).
32. Hijazi, H., Wu, M., Nath, A. & Chan, C. Ensemble classification of cancer types and biomarker identification. Drug development research 73, 414–419 (2012).
33. Kohavi, R. & John, G. H. Wrappers for feature subset selection. Artificial intelligence 97, 273–324 (1997).
34. Kashyap, P. C., Chia, N., Nelson, H., Segal, E. & Elman, E. In Mayo Clinic Proceedings. 1855–1864 (Elsevier).
35. Zeller, G. et al. Potential of local microbiota for early-stage detection of colorectal cancer. Mol Syst Biol 10, 766, https://doi.org/10.15252/msb.20145645 (2014).
36. Chang, C.-D., Wang, C.-C. & Jiang, B. C. Using data mining techniques for multi-diseases prediction modeling of hypertension and hyperlipidemia by common risk factors. Expert systems with applications 38, 5507–5513 (2011).
37. Aapro, M., Scottie, F., Bouillet, T., Currrow, D. & Viganò, A. A practical approach to fatigue management in colorectal cancer. Clinical colorectal cancer 16, 275–285 (2017).
38. Muscaritoli, M. et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG)“cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clinical nutrition 29, 154–159 (2010).
39. Kingwell, E. et al. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain 135, 2973–2979 (2012).
40. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Nature methods 7, 335–336 (2010).
41. DeSantis, T. Z. et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Applied and environmental microbiology 72, 5606–5607 (2006).
42. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
46. Heo, J. et al. Gut microbiota Modulated by Probiotics and Garcinia cambogia Extract Correlate with Weight Gain and Adipocyte Sizes in High Fat-Fed Mice. Scientific Reports 6 (2016).
47. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the royal statistical society. Series B (Methodological), 289–300 (1995).
48. Bolstad, B. M., Irizarry, R. A., Åstrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185–193 (2003).
49. Wu, Z. & Arvey, M. J. Subset quantile normalization using negative control features. Journal of Computational Biology 17, 1385–1395 (2010).
50. Hsu, C.-W. & Lin, C.-J. A comparison of methods for multiclass support vector machines. IEEE transactions on Neural Networks 13, 415–423 (2002).
51. Landwehr, N., Hall, M. & Frank, E. Logistic model trees. Machine Learning 59, 161–205 (2005).
52. Friedman, J., Hastie, T. & Tibshirani, R. Additive logistic regression: a statistical view of boosting (with discussion and a rejoinder by the authors). The annals of statistics 28, 337–407 (2000).
53. Cai, Y.-D., Feng, K.-Y., Lu, W.-C. & Chou, K.-C. Using LogitBoost classifier to predict protein structural classes. Journal of theoretical biology 238, 172–176 (2006).
54. Kim, K. et al. Application of LogitBoost Classifier for Traceability Using SNP Chip Data. PloS one 10, e0139685 (2015).
55. Altmann, A. et al. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance. Antiviral therapy 12, 169 (2007).
56. Jiao, Y. et al. Predictive models of autism spectrum disorder based on brain regional cortical thickness. Neuroimage 50, 589–599 (2010).
57. Hornik, K., Zeileis, A., Hothorn, T. & Buchta, C. RWeka: an R interface to Weka. R package version 0, 3–2 (2007).
58. Saeys, Y., Inza, I. & Larrañaga, P. A review of feature selection techniques in bioinformatics. bioinformatics 23, 2507–2517 (2007).

Acknowledgements
The authors thank Rural Development Administration for support. This research was supported by a Grant (14162MFDS972) from Ministry of Food and Drug Safety, Korea in 2018.

Author Contributions
All authors were involved in this experiment, drafting the article or revising it critically for important intellectual content. Sohyun Bang and Heebal Kim were responsible for analyzing the data and wrote the draft of the manuscript. DongAhn Yoo contributed to the interpretation of the finding. Soyun Jhang participated in additional analysis during revision. SooJin Kim and Seoae Cho contributed to review the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-46249-x.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019